# Goodbody Health announces Annual General and Special Meeting of Shareholders

- Link: https://www.directorstalkinterviews.com/goodbody-health-announces-annual-general-and-special-meeting-of-shareholders/4121072656
- Published: 2022-07-14T07:06:40+01:00
- Author: Giles

**Goodbody Health** (AQSE: GDBY) has announced that further to its news release 
dated June 10, 2022, the Company has mailed its proxy materials, with instructions
on how to attend and vote, to its shareholders of record as of July 5, 2022 for 
its annual general and special meeting to be held on August 9, 2022 at 9 am (Pacific
time) at The Blue Building, Stubbs Lane, Beckington, Frome, BA11 6TE, United Kingdom.
The information circular dated July 8, 2022, forming part of the proxy materials,
sets out full details of the Company’s intention to de-list from the Canadian Securities
Exchange and to re-domicile the Company from the Province of British Columbia to
Guernsey, subject to shareholder approval. The information circular and proxy materials
will shortly be available at the Company’s website at [www.goodbodyhealth.com](http://www.goodbodyhealth.com/).

Goodbody intends to retain its quote on the AQSE Growth Market in London and the
OTCQB quote in the United States. Further announcements regarding the post-Continuation
trading arrangements on the AQSE Growth Market will be made in due course.

Prior to the Continuation and the De-Listing, the Company intends to consolidate
all of its issued and outstanding common shares on the basis of ten (10) pre-consolidation
shares for one (1) post-consolidated share. Goodbody Health Inc. currently has 364,962,152
common shares issued and outstanding.  Following completion of the Consolidation,
the Company would have approximately 36,496,215 common shares issued and outstanding.
The Company will also consolidate all warrants and Options to the same ratio. The
Company currently has 36,603,461 options issued and outstanding. Following completion
of the Consolidation, the Company would have approximately 3,660,346 options issued
and outstanding. The Company currently has 49,317,379 warrants issued and outstanding.
Following completion of the Consolidation, the Company would have approximately 
4,931,737 warrants issued and outstanding. Any fractional common shares resulting
from the Consolidation would be rounded to the nearest whole common share, with 
any fraction of 0.5 or above rounded up and any fraction of less than 0.5 rounded
down.  Pursuant to the Company’s current articles, the Company’s board of directors
can authorize the Consolidation by directors’ resolutions.  The Consolidation is
subject to Canadian Securities Exchange approval.

The voting results from the Meeting regarding the Continuation will not affect the
De-Listing or the Consolidation.

The Company’s proxy materials are also available on the Company’s SEDAR profile 
on [www.sedar.com](http://www.sedar.com/).

Share on: